Los Angeles Capital Management & Equity Research Inc. purchased a new position in BioTelemetry Inc (NASDAQ:BEAT) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,393 shares of the medical research company’s stock, valued at approximately $262,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. bought a new position in shares of BioTelemetry in the 3rd quarter valued at about $248,000. Comerica Bank grew its holdings in shares of BioTelemetry by 33.8% in the 3rd quarter. Comerica Bank now owns 47,605 shares of the medical research company’s stock valued at $2,575,000 after acquiring an additional 12,020 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in shares of BioTelemetry in the 3rd quarter valued at about $211,000. SG Americas Securities LLC bought a new position in shares of BioTelemetry in the 3rd quarter valued at about $145,000. Finally, Prudential Financial Inc. grew its holdings in shares of BioTelemetry by 6.6% in the 3rd quarter. Prudential Financial Inc. now owns 56,449 shares of the medical research company’s stock valued at $3,638,000 after acquiring an additional 3,483 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

BioTelemetry stock opened at $67.54 on Friday. BioTelemetry Inc has a 52 week low of $29.85 and a 52 week high of $80.92. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.96 and a quick ratio of 2.81. The stock has a market cap of $2.27 billion, a P/E ratio of 34.81 and a beta of 1.47.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Thursday, February 21st. The medical research company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.13. BioTelemetry had a return on equity of 24.46% and a net margin of 10.72%. The business had revenue of $103.60 million during the quarter, compared to analysts’ expectations of $102.84 million. During the same quarter last year, the company posted $0.32 earnings per share. BioTelemetry’s quarterly revenue was up 13.0% on a year-over-year basis. As a group, sell-side analysts predict that BioTelemetry Inc will post 1.86 EPS for the current year.

A number of equities analysts recently commented on the company. BidaskClub cut BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 18th. Sidoti set a $95.00 price target on BioTelemetry and gave the stock a “buy” rating in a report on Tuesday, February 5th. Zacks Investment Research upgraded BioTelemetry from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Tuesday, February 5th. ValuEngine upgraded BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Finally, Lake Street Capital set a $90.00 price target on BioTelemetry and gave the stock a “buy” rating in a report on Friday, February 22nd. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $75.67.

In other BioTelemetry news, VP Heather C. Getz sold 10,590 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $70.41, for a total transaction of $745,641.90. Following the completion of the sale, the vice president now directly owns 80,661 shares in the company, valued at $5,679,341.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Heather C. Getz sold 64,989 shares of the firm’s stock in a transaction that occurred on Friday, January 25th. The stock was sold at an average price of $70.09, for a total transaction of $4,555,079.01. Following the sale, the chief financial officer now owns 119,085 shares of the company’s stock, valued at $8,346,667.65. The disclosure for this sale can be found here. Insiders have sold 177,198 shares of company stock valued at $12,419,736 in the last quarter. 8.30% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This article was published by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.mareainformativa.com/news/2019/03/17/los-angeles-capital-management-equity-research-inc-takes-262000-position-in-biotelemetry-inc-beat.html.

About BioTelemetry

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Read More: Market Capitalization – What it Means for Investors

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.